Dr. Aytekin Oto is Professor of Radiology and Surgery, Dean for Clinical Affairs, head of the Faculty Practice Plan and Chief Physician at the University of Chicago. Dr. Oto has a wide range of experience and expertise in the imaging of diseases affecting abdomen and pelvis. His research interest focus is development and clinical application of novel prostate MRI acquisition and interpretation so as to facilitate and improve the efficiency of prostate cancer and develop image guided prostate therapy options for the appropriate patients diagnosed with prostate cancer. His research has resulted in more than 250 publications and over 150 scientific exhibits at national and international meetings. The two overarching aims of his research are “non-invasive and accurate diagnosis of aggressive prostate cancer using MR imaging“ and “eradication of localized prostate cancer with minimal complications using minimally invasive treatment methods”. His group has developed new quantitative MR acquisition and interpretation techniques such Hybrid Multi-dimensional MRI and tested MR guided therapy methods such as laser and focused ultrasound ablation in clinical and pre-clinical studies. He has several industry, foundation and NIH grants and serves at the Editorial Board of Radiology. Dr. Oto received numerous awards including AIMBE fellowship, Distinguished Investigator Award, RSNA honored educator award and Distinguished Senior Clinician Award.
Cleveland Clinic Foundation
Cleveland, Ohio
- Abdominal Imaging Fellowship
1998
Hacettepe University
Ankara, Turkey
- Diagnostic Radiology
1997
Hacettepe University
Ankara, Turkey
MD - Medical School
1993
Surveillance After Focal Therapy for Prostate Cancer: A Comprehensive Review.
Surveillance After Focal Therapy for Prostate Cancer: A Comprehensive Review. Cancers (Basel). 2025 Apr 16; 17(8).
PMID: 40282513
Requirements for AI Development and Reporting for MRI Prostate Cancer Detection in Biopsy-Naive Men: PI-RADS Steering Committee, Version 1.0.
Requirements for AI Development and Reporting for MRI Prostate Cancer Detection in Biopsy-Naive Men: PI-RADS Steering Committee, Version 1.0. Radiology. 2025 Apr; 315(1):e240140.
PMID: 40232134
Physics-Informed Autoencoder for Prostate Tissue Microstructure Profiling with Hybrid Multidimensional MRI.
Physics-Informed Autoencoder for Prostate Tissue Microstructure Profiling with Hybrid Multidimensional MRI. Radiol Artif Intell. 2025 Mar; 7(2):e240167.
PMID: 39907585
Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment.
Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment. Radiol Imaging Cancer. 2025 Jan; 7(1):e240156.
PMID: 39836080
Introduction to matrix-based method for analyzing hybrid multidimensional prostate MRI data.
Introduction to matrix-based method for analyzing hybrid multidimensional prostate MRI data. J Appl Clin Med Phys. 2025 Jan; 26(1):e14544.
PMID: 39568316
ACR Appropriateness Criteria® Acute Onset of Scrotal Pain-Without Trauma, Without Antecedent Mass: 2024 Update.
ACR Appropriateness Criteria® Acute Onset of Scrotal Pain-Without Trauma, Without Antecedent Mass: 2024 Update. J Am Coll Radiol. 2024 Nov; 21(11S):S364-S371.
PMID: 39488348
ACR Appropriateness Criteria® Pretreatment Staging of Urothelial Cancer: 2024 Update.
ACR Appropriateness Criteria® Pretreatment Staging of Urothelial Cancer: 2024 Update. J Am Coll Radiol. 2024 Nov; 21(11S):S464-S489.
PMID: 39488355
Quantitative Multi-Parametric MRI of the Prostate Reveals Racial Differences.
Quantitative Multi-Parametric MRI of the Prostate Reveals Racial Differences. Cancers (Basel). 2024 Oct 16; 16(20).
PMID: 39456593
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer. Radiology. 2024 09; 312(3):e232748.
PMID: 39225603
ACR Appropriateness Criteria® Hydronephrosis on Prior Imaging-Unknown Cause.
ACR Appropriateness Criteria® Hydronephrosis on Prior Imaging-Unknown Cause. J Am Coll Radiol. 2024 Jun; 21(6S):S144-S167.
PMID: 38823942